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Myofilament	  remodeling	  and	  function	  is	  more	  impaired	  in	  peripartum	  cardiomyopathy	  compared	  to	  dilated	  1	  
cardiomyopathy	  and	  ischemic	  heart	  disease	  2	  
	  3	  
Ilse	   Anne	   Elise	   Bollen1,2,	   Elisabeth	   Ehler3,	   Karin	   Fleischanderl3,	   Floor	   Bouwman1,	   Lanette	   Kempers1,	  Melanie	  4	  
Ricke-­‐Hoch4,	  Denise	  Hilfiker-­‐Kleiner4,	  Cristobal	  Guillermo	  dos	  Remedios5,	  Martina	  Krüger6,	  Aryan	  Vink7,	  Folkert	  5	  
Wouter	  Asselbergs8,9,10,	  Karin	  Yvon	  van	  Spaendonck-­‐Zwarts2,11,	  Yigal	  Martin	  Pinto2,12,	  Diederik	  Wouter	  Dimitri	  6	  
Kuster1,	  2,,	  Jolanda	  van	  der	  Velden1,	  2,13	  7	  
	  8	  
1Department	  of	  Physiology,	  VU	  University	  Medical	  Center,	  Amsterdam,	  the	  Netherlands.	  	  9	  
2Amsterdam	  Cardiovascular	  Sciences,	  Amsterdam,	  the	  Netherlands	  10	  
3Randall	  Division	  of	  Cell	  and	  Molecular	  Biophysics	  and	  Cardiovascular	  Division,	  British	  Heart	  Foundation	  Centre	  11	  
of	  Research	  Excellence,	  King's	  College	  London,	  United	  Kingdom.	  12	  
4Department	  of	  Cardiology	  and	  Angiology,	  Hannover	  Medical	  School,	  Hannover,	  Germany.	  13	  
5Bosch	  Institute,	  Discipline	  of	  Anatomy	  &	  Histology,	  University	  of	  Sydney,	  Sydney,	  Australia.	  14	  
6Institute	  of	  Cardiovascular	  Physiology,	  Heinrich-­‐Heine	  University	  Düsseldorf,	  Düsseldorf,	  Germany.	  15	  
7Department	  of	  Pathology,	  University	  Medical	  Center	  Utrecht,	  Utrecht,	  the	  Netherlands.	  16	  
8Department	  of	  Cardiology,	  Division	  Heart	  &	  Lungs,	  University	  of	  Utrecht,	  University	  Medical	  Center	  Utrecht,	  17	  
Utrecht,	  the	  Netherlands.	  18	  
9Durrer	  Center	  for	  Cardiogenetic	  Research,	  ICIN-­‐Netherlands	  Heart	  Institute,	  Utrecht,	  the	  Netherlands.	  19	  
10Institute	  of	  Cardiovascular	  Science,	  Faculty	  of	  Population	  Health	  Sciences,	  University	  College	  London,	  London,	  20	  
United	  Kingdom.	  21	  
11Department	   of	   Clinical	   Genetics,	   Academic	   Medical	   Center	   Amsterdam,	   University	   of	   Amsterdam,	  22	  
Amsterdam,	  the	  Netherlands.	  23	  
12AMC	   Heart	   Center,	   Department	   of	   Clinical	   and	   Experimental	   Cardiology,	   Academic	   Medical	   Center	  24	  
Amsterdam,	  University	  of	  Amsterdam,	  Amsterdam,	  the	  Netherlands.	  25	  
13Netherlands	  Heart	  Institute,	  Utrecht,	  the	  Netherlands.	  26	  
	  27	  
Corresponding	  author:	  28	  
Ilse	  Bollen	  29	  
2	  
	  
Dept.	  of	  Physiology	  1	  
VU	  University	  Medical	  Center	  2	  
De	  Boelelaan	  1117,	  room	  11W53	  3	  
1081	  HV	  Amsterdam,	  the	  Netherlands	  4	  
Phone:	  +31627339910	  5	  
e-­‐mail:	  a.bollen@vumc.nl	  6	  
	  7	  
Running	  head:	  PPCM	  differs	  from	  DCM	  and	  ISHD	  8	  
Number	  of	  text	  pages:	  28	  9	  
Number	  of	  figures:	  6	  10	  
Funding:	   Dutch	   Heart	   Foundation	   CVON2011-­‐11	   ARENA,	   British	   Heart	   Foundation,	   Rembrandt	   Institute	   for	  11	  
Cardiovascular	   Sciences	   2013,	   Dekker	   Scholarship-­‐Junior	   Staff	   Member	   2014T001	   –	   Netherlands	   Heart	  12	  
Foundation	  and	  UCL	  Hospitals	  NIHR	  Biomedical	  Research	  Centre.	  13	  





Peripartum	   cardiomyopathy	   (PPCM)	   and	   dilated	   cardiomyopathy	   (DCM)	   show	   similarities	   in	   clinical	  3	  
presentation.	  However,	  while	  DCM	  patients	  do	  not	  recover	  and	  slowly	  deteriorate	  further,	  PPCM	  patients	  show	  4	  
either	   a	   fast	   cardiac	   deterioration	   or	   complete	   recovery.	   The	   aim	   of	   this	   study	   was	   to	   assess	   if	   underlying	  5	  
cellular	  changes	  can	  explain	  the	  clinical	  similarities	  and	  differences	  in	  the	  two	  diseases.	  We	  therefore	  assessed	  6	  
sarcomeric	  protein	  expression,	  modification,	  titin	  isoform	  shift,	  and	  contractile	  behavior	  of	  cardiomyocytes	  in	  7	  
heart	   tissue	   of	   PPCM	   and	   DCM	   patients	   and	   compared	   these	   to	   non-­‐failing	   controls.	   Heart	   samples	   from	  8	  
ischemic	  heart	  disease	  (ISHD)	  patients	  served	  as	  heart	  failure	  control	  samples.	  Passive	  force	  was	  only	  increased	  9	  
in	  PPCM	  samples	  compared	  to	  controls	  while	  PPCM,	  DCM	  and	  ISHD	  samples	  all	  showed	  increased	  myofilament	  10	  
Ca2+-­‐sensitivity.	  Length-­‐dependent	  activation	  was	  significantly	   impaired	   in	  PPCM	  compared	  to	  controls,	  while	  11	  
no	   impairment	   was	   observed	   in	   ISHD	   samples	   and	   DCM	   showed	   an	   intermediate	   response.	   Contractile	  12	  
impairments	   were	   caused	   by	   impaired	   PKA-­‐mediated	   phosphorylation	   since	   exogenous	   PKA	   restored	   all	  13	  
parameters	   to	  control	   levels.	  While	  DCM	  samples	  showed	  re-­‐expression	  of	  EH-­‐myomesin,	  an	   isoform	  usually	  14	  
only	  expressed	  in	  the	  heart	  before	  birth,	  PPCM	  and	  ISHD	  did	  not.	  The	  lack	  of	  EH-­‐myomesin,	  combined	  with	  low	  15	  
PKA-­‐mediated	  phosphorylation	  of	  myofilament	  proteins	  and	  increased	  compliant	  titin	  isoform,	  may	  explain	  the	  16	  





Clinical	  presentation	  3	  
Dilated	  cardiomyopathy	   (DCM)	  and	  peripartum	  cardiomyopathy	   (PPCM)	  are	  distinct	   forms	  of	   cardiac	  disease	  4	  
that	   share	   aspects	   of	   clinical	   presentation	   such	   as	   dilated	   ventricle(s),	   reduced	   systolic	   function	   and	   cardiac	  5	  
rhythm	  disorders1,	  2.	  PPCM	  is	  a	  cardiac	  disease	  that	  presents	  itself	  during	  the	  last	  month	  of	  pregnancy,	  during	  6	  
delivery	   or	   within	   the	   first	   5	   months	   post	   partum2.	   A	   genetic	   cause	   for	   both	   DCM	   and	   PPCM	   has	   been	  7	  
demonstrated	   before3-­‐6.	   Evidence	   has	   accumulated	   showing	   that	   about	   15-­‐20%	   of	   PPCM	   patients	   carry	  8	  
cardiomyopathy-­‐causing	  mutations	  mainly	  in	  TTN,	  MYH7	  and	  SCN5A,	  genes	  in	  which	  mutations	  are	  associated	  9	  
with	   DCM	   as	  well3.	   PPCM	   patients	   are	   often	   young	   and	   show	   fast	   cardiac	   deterioration	   after	   disease	   onset	  10	  
leading	  to	  the	  need	  for	  heart	  transplantation	  or	  death7-­‐10.	  In	  contrast,	  DCM	  patients	  develop	  cardiac	  disease	  at	  11	  
older	  age	  with	  a	  milder	  disease	  progression	  compared	  to	  PPCM11.	  While	  PPCM	  patients	  can	  show	  fast	  cardiac	  12	  
deterioration,	  they	  often	  can	  be	  stabilized	  or	  even	  show	  complete	  recovery	  upon	  treatment7-­‐14.	  In	  a	  cohort	  of	  13	  
182	  PPCM	  patients	  in	  the	  United	  States	  of	  America	  27%	  showed	  full	  recovery,	  while	  25%	  experienced	  at	  least	  14	  
one	  major	   adverse	   event,	   defined	   as	   death	  or	   complications	   that	  were	   life-­‐threatening	  or	   lead	   to	   long-­‐term	  15	  
morbidity15.	  Of	  the	  patients	  who	  survived	  a	  major	  adverse	  event,	  but	  did	  not	  receive	  a	  cardiac	  transplantation,	  16	  
7	   (32%)	   suffered	   from	   residual	   brain	   damage.	   Of	   the	   cohort	   13	   patients	   died	   within	   8	   years,	   of	   which	   5	  17	  
suddenly,	   and	   11	   underwent	   cardiac	   transplantation	  within	   2	   years	   after	   diagnosis.	   Cardiopulmonary	   arrest	  18	  
occurred	  in	  6	  patients	  either	  during	  delivery	  or	  within	  the	  first	  6	  days	  after	  delivery.	  Severe	  pulmonary	  edema	  19	  
requiring	  intensive	  care	  occurred	  in	  16	  patients	  within	  one	  week	  after	  delivery15.	  This	  cohort	  clearly	  illustrates	  20	  
the	   fast	   cardiac	   deterioration	   in	   PPCM	   patients.	   A	   German	   cohort	   of	   115	   PPCM	   patients	   reported	   an	  21	  
improvement	  rate	  of	  85%,	  full	  recovery	  rate	  of	  47%,	  a	  15%	  failure	  to	  recover	  and	  death	  in	  2%13,	  demonstrating	  22	  




	  Interestingly,	  DCM	  patients	  who	  become	  pregnant	  are	  more	  likely	  to	  experience	  adverse	  cardiac	  events	  such	  27	  
as	  heart	  failure,	  sustained	  arrhythmia,	  or	  stroke	  earlier	  in	  pregnancy16	  than	  PPCM	  patients.	  This	  is	  likely	  caused	  28	  
by	  an	  increased	  hemodynamic	  load	  on	  an	  already	  troubled	  heart.	  In	  contrast,	  increased	  cardiac	  strain	  does	  not	  29	  
5	  
	  
appear	   to	   be	   a	   disease	   trigger	   for	   PPCM	  as	   the	   highest	   incidence	  of	   disease	   onset	   is	   not	   at	   the	   time	  of	   the	  1	  
largest	  increase	  in	  hemodynamic	  load	  (approximately	  24	  weeks),	  but	  rather	  in	  the	  first	  month	  postpartum10.	  In	  2	  
addition,	  it	  has	  been	  shown	  that	  the	  hormone	  prolactin	  plays	  a	  key	  role	  in	  PPCM	  pathogenesis.	  High	  levels	  of	  3	  
oxidative	   stress	   induces	   cleavage	   of	   the	   breast-­‐feeding	   hormone	   prolactin	   into	   a	   16	   kDa	   fragment	   that	   has	  4	  
detrimental	  effects	  on	  cardiac	  function7,	  17,	  18.	  The	  peak	  of	  prolactin	  levels	  coincides	  with	  the	  peak	  incidence	  of	  5	  
disease	  onset	   in	  PPCM	  and	  while	  prolactin	   levels	  are	   low	   in	  non-­‐pregnant	  and	  non-­‐nursing	   individuals19,	   it	   is	  6	  
unlikely	   that	   prolactin	   plays	   a	   role	   in	   DCM.	   A	   recent	   study	   suggests	   detrimental	   effects	   of	   catecholamine	  7	  
treatment,	   specifically	   with	   the	   β1-­‐adrenergic	   receptor	   agonist	   dobutamine	   in	   PPCM	   patients13,	   20.	   In	   fact,	  8	  
experimental	  data	  showed	  that	  β1-­‐receptor	  agonist	  isoproterenol	  impaired	  fatty	  acid	  and	  glucose	  uptake20.	  The	  9	  
resulting	  energy	  depletion	  increased	  production	  of	  reactive	  oxygen	  species	  and	  led	  to	  cardiomyocyte	  death	  and	  10	  
progression	  of	  heart	  failure	   in	  STAT3	  knock	  out	  mice	  which	  could	  be	  attenuated	  with	  β-­‐blocker	  metoprolol20.	  11	  
Based	   on	   differences	   in	   disease	   onset	   and	   progression,	   we	   hypothesize	   that	   different	   cellular	   remodeling	  12	  
underlies	  PPCM	  and	  DCM.	  	  13	  
	  14	  
We	  studied	  myofilament	  functional	  and	  structural	  remodeling	  in	  PPCM	  and	  DCM	  compared	  to	  ischemic	  heart	  15	  
disease	  (ISHD)	  and	  non-­‐failing	  controls	  to	  define	  common	  and	  unique	  pathomechanisms	  for	  PPCM	  and	  DCM.	  16	  
We	  show	  that	  both	  PPCM	  and	  DCM	  patients	   suffer	   from	   increased	  myofilament	  Ca2+-­‐sensitivity	  and	   reduced	  17	  
myofilament	   length-­‐dependent	   activation	   compared	   to	   controls.	   The	   changes	   in	   PPCM	   samples	   were	   more	  18	  
severe	  than	  observed	  in	  DCM	  samples,	  while	  ISHD	  samples	  only	  showed	  an	  increased	  Ca2+-­‐sensitivity	  without	  19	  
an	   impairment	   in	   length-­‐dependent	   activation.	   In	   addition,	   PPCM	   patients	   showed	   a	   significant	   increase	   in	  20	  
passive	  force	  (Fpass)	  development	  compared	  to	  controls,	  while	  DCM	  and	   ISHD	  samples	  showed	  similar	  Fpass	  as	  21	  
controls.	   Also	  myofilament	   remodeling	  was	   different	   between	  DCM	   and	   PPCM	  patients.	  While	   both	   patient	  22	  
groups	  showed	  a	  similar	  increase	  in	  compliant	  titin	  and	  fibrosis,	  only	  DCM	  patients	  expressed	  the	  EH-­‐myomesin	  23	  
isoform	  which	   could	   have	   contributed	   to	   the	   observed	  differences	   in	   contractile	   force	   of	  myofilaments.	   The	  24	  
lack	   of	   a	   stabilizing	   effect	   of	   EH-­‐myomesin	   in	   PPCM	   may	   play	   a	   key	   role	   in	   the	   short-­‐term	   fast	   disease	  25	  
progression	  observed	   in	  PPCM.	  On	  the	  other	  hand,	   limited	  remodeling	  might	  also	  explain	   total	   recovery	   in	  a	  26	  





Ethical	  approval	  1	  
Left	  ventricular	  (LV)	  tissue	  from	  DCM,	  PPCM	  and	  ISHD	  samples	  were	  acquired	  from	  the	  University	  of	  Sydney,	  2	  
Australia,	  with	  the	  ethical	  approval	  of	  the	  Human	  Research	  Ethics	  Committee	  #2012/2814.	  The	  codes	  of	  used	  3	  
samples	  are;	  DCM:	  3.107,	  4.036,	  3.133,	  4.125,	  2.082	  and	  3.042,	  PPCM	  samples:	  2.048,	  3.058,	  3.118,	  4.127,	  ISHD	  4	  
samples:	  4.111,	  4.108,	  4.070,	  4.091.	  As	  control	  samples	  we	  used	  explanted	  LV	  heart	  tissue	  of	  healthy	  donors;	  5	  
people	  died	   from	  a	  non-­‐cardiac	   cause,	   typically	  motor	   vehicle	   accidents.	   These	  healthy	  donor	   samples	  were	  6	  
also	  acquired	   from	   the	  University	  of	   Sydney,	  Australia	   and	   samples	   included	  are:	  3.162,	  6.042,	  3.141,	  3.164,	  7	  
5.086,	   6.034,	   8.004,	   7.040,	   7.054,	   6.008,	   5.128,	   7.044,	   4.104,	   6.020,	   3.160	   and	   6.056.	   In	   addition,	   2	   DCM	  8	  
samples	  were	  acquired	  from	  the	  Biobank	  of	  the	  University	  Medical	  Center	  Utrecht,	  the	  Netherlands.	  This	  study	  9	  
was	   approved	   by	   the	   Biobank	   Research	   Ethics	   Committee,	   University	   Medical	   Center	   Utrecht,	   Utrecht,	   the	  10	  
Netherlands	  (protocol	  number	  WARB	  12/387).	  Written	  informed	  consent	  was	  obtained.	  Of	  the	  PPCM	  samples,	  11	  
2	   samples	   were	   acquired	   from	   at	   the	   University	   of	   Hannover,	   Germany.	   One	   sample	   was	   obtained	   during	  12	  
implantation	  of	   LV	  assist	  device	  during	   the	  acute	  phase	  of	  PPCM	  and	   the	  other	  after	   cardiac	   transplantation	  13	  
after	   chronic	   heart	   failure.	   PPCM	   tissue	   analyses	   were	   approved	   by	   the	   local	   ethics	   commission	   of	   the	  14	  
Hannover	  Medical	  School,	  both	  patients	  provided	  written	  informed	  consent.	  All	  samples	  were	  stored	  in	  liquid	  15	  
nitrogen	  or	  at	  -­‐80ᵒC	  until	  use.	  	  16	  
	  17	  
Fibrosis	  18	  
Cryosections	  of	  5	  μm	  were	  stained	  with	  picro-­‐Sirius	   red.	  The	  amount	  of	   fibrosis	  was	  quantified	  using	   ImageJ	  19	  
version	   1.49.	   The	   fibrotic	   area	  was	   selected	   using	   Huang	   thresholding	  method,	   threshold	   colour	   red,	   colour	  20	  
space	  RGB,	  wide	  open	  blue	   and	   red	   filters	   and	   adjusted	   green	   filter	   to	   distinguish	   stained	   from	  non-­‐stained	  21	  
areas.	   The	  percentage	  of	   fibrosis	  was	   calculated	  as	   the	  percentage	  of	   red	   stained	   tissue	   relative	   to	   the	   total	  22	  
area	  of	  the	  picture	  analysed.	  Of	  each	  sample	  at	  least	  3	  pictures	  were	  taken	  and	  data	  are	  shown	  as	  the	  average	  23	  
per	  sample.	  24	  
	  25	  
Cardiomyocyte	  force	  measurements	  26	  
Maximal	  force	  (Fmax)	  and	  passive	  force	  (Fpass)	  of	  sarcomeres	  were	  measured	  at	  pCa	  4.5	  and	  pCa	  9.0	  respectively	  27	  
in	   single	   membrane-­‐permeabilized	   cardiomyocytes	   mechanically	   isolated	   from	   heart	   tissue	   as	   previously	  28	  
described21,	  22.	  Briefly,	  a	  small	  piece	  of	  tissue	  (10-­‐15	  mg)	  was	  defrosted	  in	  4ᵒC	  isolation	  relax	  solution	  containing	  29	  
7	  
	  
1	  mM	  free	  Mg,	  139.6	  mM	  KCl,	  2	  mM	  EGTA,	  5.95	  mM	  ATP	  and	  10	  mM	  imidazole	  with	  pH	  adjusted	  to	  7.0	  with	  1	  
KOH.	  The	  tissue	  was	  cut	  in	  small	  pieces	  and	  mechanically	  disrupted	  with	  a	  Teflon	  piston	  for	  5-­‐10	  seconds	  at	  900	  2	  
rpm	  to	  obtain	  a	  suspension	  of	  single	  cells,	  small	  clumps	  of	  cells	  and	  cell	  fragments.	  In	  order	  to	  permeabilize	  the	  3	  
membranes	  the	  cell	  were	  incubated	  with	  0.5%	  TritonX-­‐100	  (Millipore)	  for	  5	  minutes	  at	  4ᵒC.	  Cells	  were	  washed	  4	  
with	   isolation	   relax	   solution	   to	   remove	   Triton	   and	   kept	   at	   4ᵒC	   until	   measurement	   on	   the	   same	   day.	   Single	  5	  
cardiomyocytes	  were	  selected	   for	  measurement	  based	  on	  size	   (100-­‐150	  μm	   long	  and	  10-­‐35	  μm	   in	  diameter)	  6	  
and	  uniformity	  of	  striation	  pattern.	  Single	  cardiomyocytes	  were	  attached	  to	  stainless	  steel	  needles	  attached	  to	  7	  
a	   force	   transducer	   and	   a	   length	   motor	   with	   silicon	   based	   glue	   (DB-­‐025,	   Zwaluw,	   Den	   Braven)	   while	   being	  8	  
viewed	   with	   an	   inverted	   microscope	   at	   320x	   magnification.	   Sarcomere	   length	   was	   determined	   by	   spatial	  9	  
Fourier	  transformation	  and	  set	  at	  the	  desired	  sarcomere	  length	  prior	  to	  force	  measurement	  starting	  with	  the	  10	  
smallest	   sarcomere	   length.	  The	   relax	   (pCa	  9.0)	  and	  activation	   (pCa	  4.5)	   solutions	  contained	   respectively	  6.48	  11	  
and	   6.28	   mM	   MgCl,	   5.89	   and	   5.97	   mM	   Na2ATP,	   6.97	   and	   0	   mM	   Ethylene	   glycol-­‐bis(2-­‐aminoethylether)-­‐12	  
N,N,N′,N′-­‐tetraacetic	  acid	  (EGTA)	  and	  0	  and	  7	  mM	  Ca2+–EGTA.	  Both	  relax	  and	  activation	  solution	  also	  contained	  13	  
14.5	  mM	  creatine	  phosphate	  and	  100	  mM	  N,N-­‐bis[2-­‐hydroxyethyl]-­‐2-­‐aminoethane-­‐sulphonic	  acid	  of	  which	  the	  14	  
pH	  was	  adjusted	  to	  7.1	  with	  KOH.	  The	  ionic	  strength	  of	  the	  solutions	  were	  adjusted	  to	  	  200	  mM	  with	  potassium	  15	  
propionic	  acid.	  The	  submaximal	  pCa	  solutions	  were	  created	  by	  appropriate	  mixing	  of	  the	  relax	  and	  activation	  16	  
solutions.	  A	  single	  batch	  of	  pCa	  solutions	  was	  used	  for	  all	  active	  force	  measurements	  in	  this	  study	  in	  order	  to	  17	  
eliminate	  bias	  due	  to	  batch-­‐to-­‐batch	  variation.	  All	  passive	  and	  active	  force	  measurements	  were	  performed	  at	  18	  
15ᵒC	   to	   assure	   stability	   of	   the	   cell	   during	   measurement	   and	   temperature	   was	   controlled	   with	   a	   circulating	  19	  
water	   bath.	   For	   active	   force	  measurements	   cells	   were	   transferred	   to	   the	   desired	   pCa	   (-­‐log[Ca2+])	   and	   force	  20	  
development	  was	   recorded	  until	   steady	  state	  had	  been	  reached.	  Cells	  were	   then	  shortened	  with	  30%	  of	  cell	  21	  
length	  in	  order	  to	  detach	  cross	  bridges	  and	  to	  determine	  total	  force	  development.	  Cells	  were	  then	  transferred	  22	  
back	   to	   a	   relax	   solution	   and	   shortened	   again	   with	   30%	   of	   cell	   length	   in	   order	   to	   calculate	   passive	   force	  23	  
development.	  Active	  force	  development	  was	  calculated	  by	  substraction	  of	  passive	  force	  from	  total	  force.	  Force	  24	  
was	  measured	   in	   activation	   solution	   (pCa	   4.5)	   first	   to	   obtain	  maximal	   force	   development	   and	   thereafter	   at	  25	  
different	  pCa	  solutions	  in	  a	  random	  order.	  Finally,	  force	  was	  measured	  again	  in	  activation	  solution	  in	  order	  to	  26	  
confirm	  the	  cardiomyocyte	  did	  not	  suffer	  from	  inappropriate	  	  reduction	  in	  maximal	  force	  during	  measurement	  27	  
protocol.	  Relative	  forces	  during	  experiment	  were	  corrected	  for	  decrease	  in	  maximal	  force	  during	  the	  protocol	  28	  
and	  measurements	  were	  excluded	  if	  the	  decrease	  in	  force	  was	  >30%.	  Passive	  force	  curves	  were	  measured	  by	  29	  
8	  
	  
stretching	  the	  cell	  to	  various	  sarcomere	  lengths	  and	  measurement	  of	  passive	  force	  in	  relax	  solution.	  All	  forces	  1	  
were	   normalized	   to	   cross	   sectional	   area	   of	   the	   cardiomyocytes,	   calculated	   as	   (width*	   depth*π)/4,	   at	   a	  2	  
sarcomere	   length	  of	  2.3μm.	  Protein	  kinase	  A	   (PKA)	   incubations	  were	  performed	  as	  previously	  described22.	   In	  3	  
short,	  membrane	  permeabilized	  cardiomyocytes	  were	   incubated	  with	  80	  μl	  1unit/μl	  PKA	  (P5511,	  Sigma)	  with	  4	  
0.006	  mM	  cAMP	   (Sigma)	   in	   isolation	   relax	   solution	  at	  20ᵒC	   for	  40	  minutes	  prior	   to	  measurement	  of	   force	  at	  5	  
15ᵒC	  according	  to	  the	  same	  protocol	  described	  above	  without	  prior	  PKA	  incubation.	  Relative	  force-­‐[Ca2+]	  curves	  6	  
were	   constructed	   and	   Ca2+-­‐sensitivity	  was	  measured	   as	   the	   [Ca2+]	   needed	   to	   achieve	   50%	  of	   Fmax	   (EC50)	   and	  7	  
length-­‐dependent	  activation	  was	  measured	  as	  the	  shift	  in	  EC50	  (ΔEC50)	  at	  a	  sarcomere	  length	  of	  1.9	  μm	  and	  2.3	  8	  
μm.	  A	   representation	   of	   how	  EC50	   and	  ΔEC50	  were	   calculated	   can	   be	   found	   in	   Supplemental	   Figure	   S1.	   	   The	  9	  
number	  of	  cardiomyocytes	  measured	  in	  each	  experiment	  is	  indicated	  as	  “n”	  and	  the	  number	  of	  patients	  these	  10	  
cardiomyocytes	  were	  derived	  from	  are	  indicated	  as	  “N”	  in	  figure	  legends.	  	  11	  
	  12	  
Protein	  expression	  and	  modification	  13	  
Titin	   isoforms	   were	   separated	   on	   a	   1%	   (w/v)	   agarose	   gel	   and	   stained	   with	   SYPRO	   Ruby	   protein	   gel	   stain	  14	  
(Invitrogen)	  as	  described	  previously23	  and	  samples	  were	  measured	  in	  triplicate.	  	  15	  
The	   size	   of	  N2BA	   titin	  was	   calculated	   as	   described	   previously24,	   25.	   In	   short,	   homogenates	   of	   the	   samples	   of	  16	  
interest	   (PPCM,	  DCM	  and	   ISHD)	  were	   loaded	  adjacent	   to	  a	  non-­‐failing	  control	  heart	  and	  soleus	  muscle	  of	  an	  17	  
adult	  mouse	  on	  a	  1%	  agarose	  gel	  and	  proteins	  were	  separated	   in	   the	  same	  way	  as	  described	  above	   for	   titin	  18	  
isoform	  composition.	  A	   calibration	  curve	  was	   constructed	  based	  on	  mobility	  of	  proteins	  of	   known	  molecular	  19	  
weight	   (N2A	   soleus	   3690	   kDa;	   N2B	   non-­‐failing	   heart	   2970	   kDa;	   nebulin	   soleus	  muscle	   748	   kDa	   and	  myosin	  20	  
heavy	  chain	  (MHC)	  200	  kDa)	  relative	  to	  MHC.	  This	  calibration	  curve	  was	  used	  to	  calculate	  the	  molecular	  weight	  21	  
of	  the	  N2BA	  titin	  band	  of	  the	  sample	  of	  interest	  based	  on	  relative	  mobility	  to	  MHC.	  An	  example	  of	  a	  calibration	  22	  
curve	  and	  the	  associated	  calculation	  to	  determine	  titin	  N2BA	  size	  is	  depicted	  in	  Supplemental	  Figure	  S2A,	  B.	  In	  23	  
order	  to	  avoid	  gel-­‐to-­‐gel	  variation	  or	  variation	   in	  mobility	  within	  a	  gel,	  only	  the	  adjacent	   lanes	  were	  used	  for	  24	  
the	  construction	  of	  the	  calibration	  curve.	  For	  all	  samples	  the	  same	  reference	  control	  sample	  was	  used	  and	  all	  25	  
samples	  were	  measured	  in	  duplicate.	  	  26	  
To	  assess	   titin	  phosphorylation	  homogenates	  were	   loaded	  on	  a	  2.1%	  acrylamide,	  0.5%	  agarose-­‐strengthened	  27	  
gel	  and	  separated	  as	  previously	  described26.	  Proteins	  were	  transferred	  to	  a	  PVDF	  membrane,	  blocked	  with	  3%	  28	  
BSA	   and	   incubated	   with	   phospho	   site-­‐specific	   antibodies	   directed	   to	   Serine-­‐4010	   	   (Ser4010;	   N2Bunique	  29	  
9	  
	  
sequence	   (N2Bus)	   domain;	   PKA	   and	   extracellular	   signal-­‐regulated	   kinase	   2	   (ERK2)	   target),	   or	   Serine-­‐12022	  1	  
(Ser12022;	   PEVK	   domain;	   protein	   kinase	   C	   (PKC)	   and	   Ca2+/calmodulin	   dependent	   protein	   kinase	   II	   (CaMKIIɗ)	  2	  
target)	   both	   from	   Eurogentech,	   Belgium.	   Incubation	   of	   primary	   antibodies	  was	   followed	   by	   incubation	  with	  3	  
secondary	   HRP-­‐conjugated	   antibody.	   Enhanced	   chemiluminescence	   detection	   kit	   (Amersham)	   was	   used	   in	  4	  
order	  to	  detect	  phosphorylated	  proteins	  with	  the	  Fuji-­‐imager	  LAS	  4000	  imager.	  Membranes	  were	  stripped	  to	  5	  
remove	  phospho-­‐specific	  antibody	  and	  blocked	  again	  with	  3%	  BSA.	  Membranes	  were	  then	  incubated	  with	  an	  6	  
antibody	   directed	   to	   total	   titin	   (Eurogentech,	   Belgium)	   and	   visualized	   with	   enhanced	   chemiluminescence	  7	  
detection	  kit	  (Amersham).	  	  8	  
Phosphorylation	  of	  cardiac	  troponin	  I	  (cTnI)	  and	  cardiac	  myosin	  binding	  protein	  C	  (cMyBP-­‐C)	  were	  assessed	  as	  9	  
previously	  described27.	  Phosphorylation	  of	  cTnI	  was	  further	  studied	  by	  phos-­‐tag	  analysis	  in	  which	  non-­‐,	  mono-­‐	  10	  
and	  bis-­‐phosphorylated	  cTnI	  (Pierce,	  MA1-­‐22700)	  were	  separated	  by	  polyacrylamide	  bound	  Mn2+-­‐phos-­‐tag	  gel	  11	  
electrophoresis	  western	  blotting	  as	  previously	  described28.	  12	  
Glutathionylation	  of	  cMyBP-­‐C	  was	  assessed	  as	  previously	  described29	  with	  minor	  deviations	  from	  protocol.	   In	  13	  
short:	   A	   non-­‐reducing	   RIPA	   buffer	  was	   used	   for	   protein	   isolation	   to	  which	   25	  mM	  N-­‐ethylmaleimide	   (NEM)	  14	  
(Sigma)	  was	  added	  prior	  to	  isolation.	  After	  protein	  isolation,	  the	  homogenate	  was	  diluted	  in	  a	  1:1	  ratio	  with	  2x	  15	  
Laemmli	  sample	  buffer	  and	  loaded	  on	  CriterionTM	  TGXTM	  Precast	  gels	  8-­‐16%	  (BioRad).	  Proteins	  were	  transferred	  16	  
to	   nitrocellulose	   membrane	   (BioRad)	   and	   blocked	   with	   5%	   blocking	   grade	   buffer	   containing	   2.5	   mM	   NEM.	  17	  
Membranes	  were	  cut	  and	   incubated	  with	  antibodies	  against	  glutathione	   (Sigma,	  ab19534)	  or	  GAPDH	   (14C10	  18	  
Cell	  signaling).	  Membranes	  were	  stripped	  (RestoreTM	  Western	  Blot	  Stripping	  Buffer,	  Thermo	  Scientific),	  blocked	  19	  
with	  5%	  blocking	  grade	  buffer	  and	  incubated	  with	  antibody	  against	  cMyBP-­‐C	  (sc-­‐67354,	  Santa	  Cruz)	  followed	  by	  20	  
incubation	  with	  secondary	  HRP-­‐conjugated	  antibody.	  Enhanced	  chemiluminescence	  kit	  (Amersham)	  was	  used	  21	  
to	   detect	   proteins	   with	   the	   Amersham	   imager	   600.	   As	   positive	   and	   negative	   controls	   for	   the	   glutathione	  22	  
western	   blot,	   cardiomyocytes	   were	   isolated	   from	   a	   male	   Wistar	   rat	   (200g).	   The	   animal	   experiments	   were	  23	  
performed	   in	   accordance	  with	   the	  guidelines	   from	  Directive	  2010/63/EU	  of	   the	  European	  Parliament	  on	   the	  24	  
protection	   of	   animals	   used	   for	   scientific	   purposes.	   Liberase	   TM30	   was	   used	   for	   isolation	   of	   adult	   rat	  25	  
cardiomyocytes	   and	   cells	   were	   suspended	   in	   plating-­‐medium	   containing	   medium	   199	   (Lonza),	  26	  
penicillin/streptomycin	  (1%)	  and	  fetal	  bovine	  serum	  (5%).	  Cardiomyocytes	  were	  carefully	  pipetted	  on	   laminin	  27	  
coated	  glass	   coverslips.	  One	  hour	   after	  plating,	   cells	   that	  were	  not	   attached	  were	   removed	  by	   replacing	   the	  28	  
plating-­‐medium	   with	   culture-­‐medium	   that	   consisted	   of	   medium	   199,	   penicillin/streptomycin	   (1%)	   and	   ITS	  29	  
10	  
	  
supplement	  (Sigma	  Aldrich,insulin	  10	  mg/l,	  transferrin	  5.5	  mg/l,	  and	  selenium	  5	  μg/l).	  Positive	  controls	  were	  rat	  1	  
cardiomyocytes	  incubated	  for	  1	  hour	  with	  various	  concentrations	  of	  the	  membrane-­‐permeable	  thiol	  oxidizing	  2	  
agent	   diamide	   (Sigma).	   Negative	   controls	   were	   homogenates	   from	   rat	   cardiomyocytes	   treated	   with	   the	  3	  
reducing	   agents	   100	   mM	   dithiothreitol	   (DTT)	   and	   1.4	   M	   β-­‐mercaptoethanol	   (BME)	   prior	   to	   loading.	   The	  4	  
glutathione	  western	  blot	  was	  confirmed	  to	  work	  since	  adding	  DTT	  and	  BME	  reduced	  the	  glutathione	  signal	  and	  5	  
adding	   diamide	   in	   non-­‐reducing	   conditions	   increased	   the	   glutathione	   signal	   in	   a	   dose	   dependent	   manner	  6	  
(Supplemental	  Figure	  S3A,	  B).	  	  7	  
	  8	  
EH-­‐myomesin	  expression	  immunohistochemistry	  9	  
Human	  heart	  tissue	  pieces	  were	  cut	  on	  a	  Leica	  CM	  1950	  cryostat	  and	  12	  μm	  thick	  sections	  were	  retrieved	  on	  10	  
poly-­‐lysine	  coated	  slides	  and	  dried	  overnight.	  Sections	  were	   fixed	   for	  5	  min	   in	  acetone	  at	   -­‐20°C,	   followed	  by	  11	  
brief	  rehydration	  in	  PBS	  and	  30	  min	  blocking	  in	  5%	  preimmune	  goat	  serum	  (Sigma)/1%	  bovine	  serum	  albumin	  12	  
(BSA,	  Sigma)	  in	  gold	  buffer	  (GB;	  20	  mM	  Tris-­‐HCl,	  pH	  7.5,	  155	  mM	  NaCl,	  2	  mM	  ethylene	  glycol	  tetraacetic	  acid	  13	  
[EGTA],	   2	  mM	  MgCl2).	  Mouse	  monoclonal	   anti	  myomesin	   (clone	  B4
31)	   and	   rabbit	   polyclonal	   anti	   human	   EH-­‐14	  
myomesin	  (Schoenauer	  et	  al.,	  2011;	  PMID	  21069531;	  generously	  donated	  by	  Dr	  Irina	  Agarkova)	  were	  diluted	  in	  15	  
1%	  BSA/GB	  and	   incubated	  overnight	   in	  a	  humid	  chamber.	  After	  3x	  5	  min	  wash	   in	  PBS,	   secondary	  antibodies	  16	  
(Cy3-­‐goat	  anti	  mouse	  immunoglobulins	  and	  Cy2-­‐goat	  anti	  rabbit	   immunoglobulins;	  both	  multilabelling	  quality	  17	  
from	   Jackson	   Immunochemicals	   via	   Stratech	   Scientific,	   UK)	   and	   DAPI	   were	   incubated	   for	   30	   min	   at	   room	  18	  
temperature	   in	   a	   humid	   chamber.	   After	   3x5	  min	  wash	   in	   PBS	   slides	  were	  mounted	   in	   Tris-­‐buffered	   glycerol	  19	  
containing	  n-­‐propyl	  gallate32	  with	  coverslips	  and	  were	  sealed	  with	  nail	  polish.	  Imaging	  was	  carried	  out	  using	  a	  20	  
Leica	  SP5	  confocal	  microscope	  equipped	  with	  a	  405	  nm	  blue	  diode	  and	  argon	  and	  helium	  neon	  lasers	  and	  oil	  21	  
immersion	  lenses.	  22	  
	  23	  
EH-­‐myomesin	  expression	  Westernblot	  24	  
Following	   SDS-­‐PAGE	  on	   a	   4-­‐8%	  TruPAGE	  Precast	  Gel	   (Sigma)	   at	   120V,	   the	  human	  heart	   tissue	   samples	  were	  25	  
transferred	   overnight	   onto	   nitrocellulose	   (GE	  Healthcare	  Amersham)	   using	   a	   Bio-­‐Rad	  Wet	   Blot	   system	   at	   55	  26	  
mA.	  Transfer	  was	  visualised	  with	  Ponceau	  Red,	  followed	  by	  blocking	  in	  5%	  non-­‐fat	  dry	  milk	  (Sainsbury's)	  in	  Low	  27	  
Salt	  Buffer	  for	  one	  hour.	  After	  incubation	  with	  primary	  antibody	  against	  human	  EH-­‐myomesin32	  and	  secondary	  28	  
antibody	  (HRP-­‐conjugated	  goat	  anti	   rabbit	   immunoglobulins;	  Calbiochem),	  the	  chemiluminescence	  signal	  was	  29	  
11	  
	  
visualised	  using	  Clarity	  Western	  ECL	  Substrate	   (Bio-­‐Rad)	  and	  detected	  with	  a	  Bio-­‐Rad	  ChemiDoc	  Gel	   Imaging	  1	  
System.	  For	  quantification,	  blots	  were	   reprobed	  with	  a	  polyclonal	  antibody	  against	  all	   actin	   isoforms	   (Sigma)	  2	  
and	   densitometry	   was	   carried	   out	   using	   a	   Mathematica	   algorithm	   generously	   provided	   by	   Dr	   Mark	   Holt	  3	  
(Randall	  Division,	  King's	  College	  London).	  4	  
	  5	  
Statistics	  6	  
Graphpad	   Prism	   software	  was	   used	   for	   statistical	   analysis.	   Fmax	   of	   patient	   cardiomyocytes	  was	   compared	   to	  7	  
control	   cardiomyocytes	   with	   one-­‐way	   ANOVA.	   Ca2+-­‐sensitivity	   was	   calculated	   as	   EC50	   and	   length-­‐dependent	  8	  
activation	   as	   ΔEC50.	   The	   amount	   of	   fibrosis,	   EC50,	   ΔEC50,	   N2BA/N2B	   ratio,	   phosphorylation	   of	   cTnI	   and	  9	  
glutathionylation	   of	   cMyBP-­‐C	   were	   compared	   with	   one-­‐way	   ANOVA.	   Phosphorylation	   of	   cMyBP-­‐C	   was	  10	  
compared	   between	   groups	   with	   non-­‐parametric	   Kruskal-­‐Wallis	   test.	   Fpass	   in	   patient	   cardiomyocytes	   were	  11	  
compared	   to	   control	   cardiomyocytes	   by	   2-­‐way	   ANOVA.	   Correlations	   between	   N2BA/N2B	   and	   N2BA	   size,	  12	  
N2BA/N2B	   and	   fibrosis	   and	   glutathionylation	   and	   phosphorylation	   of	   cMyBP-­‐C	   were	   studied	   with	   linear	  13	  
regression.	  All	   values	  are	   shown	  as	  means	  ±	   standard	  errors	  of	   the	  mean.	  Statistical	  analysis	  was	  performed	  14	  
with	  Graphpad	  Prism	  v7.	  A	  p-­‐value<0.05	  was	  considered	  to	  represent	  a	  significant	  difference	  and	  is	   indicated	  15	  
with	  *	  in	  figures.	  16	  
	  17	  
Results	  18	  
High	  Fpass	  and	  blunted	  length-­‐dependent	  activation	  of	  PPCM	  myofilaments	  19	  
The	  16	  control	  samples	  used	  for	  experiments	  were	  derived	  from	  7	  females	  and	  9	  males	  with	  an	  age	  of	  44.1±2.9	  20	  
years,	  the	  PPCM	  samples	  of	  6	  females	  with	  an	  age	  of	  35.7±3.2	  years,	  the	  DCM	  samples	  from	  3	  females	  and	  5	  21	  
males	  with	  an	  age	  of	  50.0±2.9	  and	  the	  ISHD	  samples	  from	  4	  males	  with	  an	  age	  of	  56.0±2.7.To	  establish	  changes	  22	  
in	  functional	  remodeling	  of	  cardiomyocytes,	  myofilament	  force	  measurements	  were	  performed	  in	  membrane-­‐23	  
permeabilized	  cardiomyocytes.	  Fmax	  was	  similar	   in	  all	  groups	  (Figure	  1A),	  while	  Fpass	  was	  significantly	  higher	  in	  24	  
PPCM	   samples	   compared	   to	   DCM,	   ISHD	   and	   controls	   (Figure	   1B).	   Ca2+-­‐sensitivity	   of	   myofilaments	   was	  25	  
significantly	  higher	  in	  all	  patient	  groups	  compared	  to	  controls,	  evident	  from	  the	  leftward	  shift	  of	  the	  Force-­‐Ca2+	  26	  
relationship	   (Figure	   1C)	   and	   significantly	   lower	   EC50	   in	   PPCM,	   DCM	   and	   ISHD	   samples	   compared	   to	   controls	  27	  
(Figure	  1D).	  Length-­‐dependent	  activation	  of	  myofilaments,	  indicated	  by	  the	  slope	  of	  the	  curve	  in	  Figure	  1E,	  was	  28	  
lower	  in	  PPCM	  and	  DCM	  samples,	  but	  not	  in	  ISHD	  samples	  compared	  to	  controls.	  The	  drop	  in	  length-­‐dependent	  29	  
12	  
	  
activation,	  expressed	  as	  ΔEC50,	  was	   largest	   in	  PPCM	  samples	  and	   significantly	  different	   from	  controls	   (Figure	  1	  
1F).	  	  2	  
	  3	  
More	  compliant	  titin	  and	  fibrosis	  in	  PPCM	  and	  DCM	  but	  not	  in	  ISHD	  4	  
Titin	   is	   a	   giant	   sarcomeric	   protein	   that	   spans	   the	   entire	   sarcomere	   from	   the	   Z-­‐disk	   to	   the	   M-­‐band	   and	   is	  5	  
important	   in	  the	  regulation	  of	  Fpass	   through	   isoform	  switching	  and	  phosphorylation
33.	   In	  addition,	   it	  has	  been	  6	  
suggested	   that	  a	   switch	   to	   the	  more	   compliant	   titin	   isoform	   leads	   to	   reduced	   LDA34,	   35.	   Titin	   can	  exist	   in	   the	  7	  
small	  and	  stiff	  N2B	  isoform,	  and	  longer	  and	  more	  compliant	  N2BA	  isoforms.	  It	  is	  has	  been	  shown	  that	  changes	  8	  
in	  titin	  isoform	  composition	  and	  phosphorylation	  contribute	  to	  DCM	  pathogenesis36,	  37.	  However,	  it	  is	  unknown	  9	  
if	   titin	   isoform	   composition	   and	   phosphorylation	   is	   altered	   in	   PPCM	  patients.	   Titin	   isoforms	  were	   separated	  10	  
with	   gel	   electrophoresis	   (Figure	   2A).	   While	   PPCM	   samples	   showed	   a	   non-­‐significant	   and	   DCM	   samples	   a	  11	  
significant	  increase	  in	  N2BA/N2B	  ratio	  compared	  to	  controls,	  ISHD	  samples	  did	  not	  differ	  from	  controls	  (Figure	  12	  
2B).	  The	  size	  of	  N2BA	  titin	  was	  also	  increased	  in	  PPCM	  and	  DCM	  samples,	  while	  a	  smaller	  increase	  in	  N2BA	  size	  13	  
was	   observed	   in	   ISHD	   samples	   compared	   to	   controls	   (Figure	   2C).	   The	   size	   of	   the	   N2BA	   titin	   isoforms	  14	  
significantly	   correlated	   with	   the	   N2BA/N2B	   ratio	   in	   DCM	   and	   PPCM	   samples,	   but	   not	   in	   ISHD	   and	   controls	  	  15	  
(Figure	  2D).	   This	   implies	   that	   there	   is	  not	  only	  more	  N2BA	   titin,	  but	   also	   larger	  N2BA	   isoforms	   in	  PPCM	  and	  16	  
DCM	  samples.	  	  17	  
The	   increase	   in	   titin	   size	   and	  N2BA/N2B	   ratio	   implies	   that	   the	   heart	   induces	   a	   response	   to	   increase	   cellular	  18	  
compliance,	  possibly	  in	  response	  to	  stiffening	  of	  the	  heart	  by	  fibrosis.	  We	  therefore	  measured	  the	  amount	  of	  19	  
fibrosis	   by	   picro-­‐Sirius	   red	   staining	   in	   the	   same	   tissue	   samples	   in	  which	  N2BA/N2B	   ratio	   and	   titin	   size	  were	  20	  
measured.	  Figure	  2E	  shows	  representative	  pictures	  of	  tissue	  samples	  in	  which	  fibrosis	  is	  stained	  in	  fierce	  red.	  A	  21	  
significant	  increase	  in	  fibrosis	  was	  found	  in	  PPCM	  and	  DCM	  samples	  compared	  to	  controls	  (Figure	  2F),	  while	  the	  22	  
increase	   in	   fibrosis	  observed	   in	   ISHD	  samples	  was	  not	  significant	  compared	  to	  controls	   (Figure	  2F).	  Figure	  2G	  23	  
illustrates	  that	  a	  higher	  level	  of	  fibrosis	  coincides	  with	  higher	  N2BA/N2B	  ratios	  in	  PPCM	  and	  DCM	  samples.	  	  24	  
	  25	  
Reduced	  phosphorylation	  and	  preserved	  glutathionylation	  of	  cMyBP-­‐C	  	  in	  end-­‐stage	  dilated	  cardiomyopathies	  26	  
Oxidative	  stress	  has	  been	  shown	  to	  play	  an	  important	  role	  in	  PPCM	  pathogenesis	  and	  is	  also	  reported	  in	  other	  27	  
forms	   of	   heart	   failure7,	   38,	   and	   may	   underlie	   the	   changes	   in	   cellular	   function.	   Oxidative	   stress	   can	   cause	  28	  
glutathionylation	   of	   various	   proteins	   and	   thereby	   alter	   their	   function39,	   40.	   Glutathionylation	   of	   cMyBP-­‐C	   has	  29	  
13	  
	  
been	  shown	  to	  impair	  phosphorylation	  of	  cMyBP-­‐C	  and	  subsequently	  decelerate	  Ca2+-­‐	  mediated	  force	  kinetics	  1	  
in	   DCM	   and	   ISHD40.	   ProQ-­‐stained	   (Figure	   3A,	   upper	   panel;	   phosphorylation)	   and	   SYPRO-­‐stained	   (Figure	   3A,	  2	  
lower	  panel;	   total	   protein)	   gel	   analysis	   showed	  decreased	  phosphorylation	  of	   cMyBP-­‐C	   (Figure	  3B)	   in	   PPCM,	  3	  
DCM	   and	   ISHD	   compared	   to	   controls.	   Western	   blots	   for	   glutathionylated	   proteins	   (Figure	   3C	   upper	   panel	  4	  
glutathionylated	  cMyBP-­‐C	  and	  Figure	  3C	  lower	  panel	  total	  cMyBP-­‐C)	  showed	  there	  was	  no	  significant	  increase	  5	  
in	   glutathionylated	   cMyBP-­‐C	   (Figure	   3D)	   in	   PPCM,	   DCM	   and	   ISHD	   samples	   compared	   to	   controls.	   Also	   no	  6	  
correlation	   was	   found	   between	   the	   amount	   of	   glutathionylated	   cMyBP-­‐C	   and	   phosphorylation	   of	   cMyBP-­‐C	  7	  
(Figure	  3E).	  This	   implies	  that	  the	  decreased	  phosphorylation	  of	  cMyBP-­‐C	   in	  these	  samples	  was	  not	  caused	  by	  8	  
glutathionylation	   of	   cMyBP-­‐C.	   The	   decreased	   phosphorylation	   of	   cMyBP-­‐C	   could	   have	   been	   caused	   by	  9	  
desensitization	   of	   the	   β-­‐adrenergic	   receptors	   and	   subsequent	   impaired	   PKA-­‐mediated	   phosphorylation,	   a	  10	  
mechanism	  confirmed	  in	  various	  forms	  of	  heart	  failure41.	  	  11	  
	  12	  
Restoration	  of	  cTnI	  and	  titin	  phosphorylation	  normalized	  Fpass,	  Ca
2+-­‐sensitivity	  and	  length-­‐	  dependent	  activation	  13	  
of	  myofilaments	  14	  
Decreased	   PKA-­‐mediated	   phosphorylation	   at	   Ser4010	   of	   titin	   could	   underlie	   the	   higher	   Fpass	   in	   PPCM
42.	  15	  
Phosphorylation	   of	   Ser4010	   was	   indeed	   decreased	   in	   PPCM	   samples	   compared	   to	   controls	   (Figure	   4A,C).	  16	  
However,	   Ser4010	   phosphorylation	  was	   also	   decreased	   in	   DCM	   (Figure	   4A,C),	   while	   Fpass	   was	   not	   altered	   in	  17	  
DCM	  samples.	  An	  alternative	  hypothesis	   for	   the	  discrepant	   change	   in	   Fpass	   in	  PPCM	  and	  DCM	  would	  be	   that	  18	  
PKC-­‐mediated	   phosphorylation	   of	   titin	   is	   increased	   in	   PPCM	   leading	   to	   an	   increased	   Fpass	  
42.	   However,	   PKC-­‐19	  
mediated	  phosphorylation	  at	  Ser12022	  was	  decreased	  rather	  than	   increased	   in	  PPCM,	  and	  unaltered	   in	  DCM	  20	  
and	  ISHD	  compared	  to	  controls	  (Figure	  2B,D).	  In	  order	  to	  determine	  if	  the	  decrease	  in	  Ser4010	  phosphorylation	  21	  
was	   causal	   to	   the	   increase	   in	   Fpass	   in	   PPCM	   samples	   we	   repeated	   the	   experiments	   after	   incubation	   with	  22	  
exogenous	   PKA.	   Indeed,	   PKA	   normalized	   Fpass	   in	   PPCM	   samples	   (Figure	   4E).	   Impaired	   PKA-­‐mediated	  23	  
phosphorylation	  could	  also	  cause	  hypophosphorylation	  of	  cTnI,	  which	  is	  an	  important	  regulator	  of	  myofilament	  24	  
Ca2+-­‐sensitivity	   and	   length-­‐dependent	   activation43,	   44.	   Indeed,	   cTnI	   phosphorylation	   	   was	   also	   decreased	   in	  25	  
PPCM,	   DCM	   and	   ISHD	   samples	   compared	   to	   controls	   (Figure	   3A,	   4F).	   A	   PhosTag	   analysis	   of	   cTnI	   showed	  26	  
prominent	  mono-­‐	  and	  bis-­‐phosphorylation	  of	  cTnI	  in	  controls	  while	  PPCM	  and	  DCM	  samples	  showed	  prominent	  27	  
non-­‐	  and	  mono-­‐phosphorylation	  of	  cTnI.	  The	  ISHD	  samples	  showed	  predominantly	  mono-­‐phosphorylated	  cTnI	  28	  
(Figure	   4G,H).	   Exogenous	   PKA	   normalized	   myofilament	   Ca2+-­‐sensitivity	   in	   PPCM,	   DCM	   and	   ISHD	   samples	   to	  29	  
14	  
	  
control	   levels	   (Figure	   4I,J).	   In	   addition,	   exogenous	   PKA	   restored	   ΔEC50	   in	   PPCM	   and	   DCM	   to	   control	   levels	  1	  
(Figure	  4K).	  	  	  2	  
	  3	  
Expression	  of	  EH-­‐myomesin	  in	  DCM	  but	  not	  in	  PPCM	  and	  ISHD	  samples	  4	  
Although	  Fpass	  normalized	  to	  control	  levels	  after	  PKA	  in	  the	  PPCM	  samples,	  we	  set	  out	  to	  find	  an	  explanation	  for	  5	  
the	   discrepant	   finding	   of	   Fpass	   and	   titin	   phosphorylation	   in	   PPCM,	   DCM	   and	   ISHD	   samples.	   Myomesin	   is	   a	  6	  
component	  of	  the	  M-­‐band	  and	  is	  important	  for	  sarcomere	  stability.	  The	  fetal	  form	  of	  myomesin,	  EH-­‐myomesin,	  7	  
has	  been	  shown	  to	  be	  a	  hallmark	  of	  DCM	  and	   is	  virtually	  absent	   in	  adult	  healthy	  heart	  tissue32.	   It	   is	  believed	  8	  
that	  EH-­‐myomesin	  is	  re-­‐expressed	  in	  order	  to	  provide	  stability	   in	  overstretched	  conditions	  in	  DCM.	  Our	  study	  9	  
confirmed	   EH-­‐myomesin	   was	   re-­‐expressed	   in	   DCM	   samples	   (Figure	   5C,G).	   Expression	   of	   EH-­‐myomesin	   was	  10	  
much	   lower	   in	   ISHD	   samples	   (Figure	   5D,H)	   and	   almost	   absent	   in	   PPCM	   samples	   (Figure	   5B,F).	   Our	   control	  11	  
patients	   did	   not	   show	   expression	   of	   EH-­‐myomesin	   or	   only	   at	   a	   very	   low	   level	   (Figure	   5A,E).	   Western	   blot	  12	  
analysis	  confirmed	  high	  EH-­‐myomesin	  expression	  in	  DCM,	  but	  not	  in	  PPCM	  and	  controls	  (Figure	  5I,	  J).	  Thus,	  the	  13	  
increase	  in	  titin	  N2BA/N2B	  ratio	  is	  accompanied	  by	  an	  increase	  in	  EH-­‐myomesin	  in	  DCM,	  but	  not	  in	  PPCM.	  The	  14	  
absence	  of	  the	  stabilizing	  effect	  of	  EH-­‐myomesin	  expression	   in	  PPCM	  may	  provide	  an	  explanation	  why	  PPCM	  15	  
showed	  more	  impairment	  of	  myofilament	  function	  compared	  to	  DCM,	  while	  titin	  isoform	  expression	  and	  PKA-­‐16	  
mediated	  myofilament	  phosphorylation	  were	  similar	  in	  the	  two	  groups.	  	  	  17	  
	  18	  
Discussion	  19	  
The	   clinical	   similarities	   and	  differences	   in	  disease	  onset,	   progression	   and	  outcome	  between	  PPCM	  and	  DCM	  20	  
patients	   suggest	   that	   the	   cellular	   pathomechanisms	   overlap,	   but	  may	   also	   show	   distinct	   changes.	   Here,	   we	  21	  
show	   that	   myofilament	   function	   is	   more	   impaired	   in	   PPCM	   compared	   to	   DCM	   with	   respect	   to	   length-­‐22	  
dependent	   activation	   and	   Fpass.	   In	   addition,	   myofilament	   remodeling	   was	   different,	   since	   DCM	   samples	  23	  
expressed	  EH-­‐myomesin,	  while	  PPCM	  samples	  did	  not.	  On	   the	  other	  hand,	  PPCM	  and	  DCM	  samples	   showed	  24	  
similar	  changes	  in	  myofilament	  Ca2+-­‐sensitivity	  and	  sarcomeric	  protein	  phosphorylation.	  	  25	  
	  26	  
Fibrosis	  content	  is	  higher	  in	  PPCM	  and	  DCM	  compared	  to	  ISHD	  and	  controls	  27	  
While	  fibrosis	  is	  consistently	  reported	  in	  DCM,	  45,	  46	  ,	  reports	  on	  the	  occurrence	  of	  fibrosis	  in	  PPCM	  patients	  are	  28	  
conflicting47-­‐50	  while	  animal	  models	  of	  PPCM	  show	  fibrosis51.	  MRI	  data	  at	  diagnosis	  of	  PPCM	  in	  patients	  display	  29	  
15	  
	  
frequently	   no	   hint	   for	   fibrosis,	   a	   feature	   that	  would	   be	   consistent	  with	   the	   ability	   of	  many	   patients	   to	   fully	  1	  
recover	   from	   the	   disease17,	   52.	   In	   the	   present	   study,	   we	   found	   fibrosis	   in	   both	   DCM	   and	   PPCM	   samples.	  2	  
However,	   it	  must	   be	   noted	   that	   the	   assessment	   of	   fibrosis	   was	   performed	   in	   small	   tissue	   areas	   of	   samples	  3	  
obtained	   during	   heart	   transplantation.	   It	   cannot	   be	   excluded	   that	   the	   tissue	   samples	  were	   selectively	   taken	  4	  
from	  more	   fibrotic	   regions	  and	  may	   thus	  not	  be	   representative	   for	  whole	  heart	   fibrosis	   content.	  Techniques	  5	  
such	  as	  magnetic	  resonance	  imaging	  (MRI)	  might	  give	  a	  better	  impression	  of	  whole	  heart	  fibrosis	  content.	  No	  6	  
late	   gadolinium	  enhancement	  by	  MRI	  was	   shown	   in	   PPCM	   (2	   acute	  phase	  patients	   and	  4	  patients	   at	   a	   later	  7	  
stage)	  previously49.	  In	  addition,	  our	  fibrosis	  analysis	  was	  only	  performed	  in	  end-­‐stage	  explanted	  heart	  tissue	  of	  8	  
PPCM	  patients	  and	  might	  therefore	  have	  been	  induced	  over	  time	  and	  may	  not	  reflect	  the	  acute	  or	  short	  term	  9	  
PPCM	  situation.	   The	   ISHD	   samples	  were	   taken	   from	   the	   remote	  area	  and	  not	  within	   the	   infarct	   zone.	  While	  10	  
PPCM	  and	  DCM	  are	  more	   likely	   to	   show	  a	  diffuse	   fibrosis	  pattern	  and	   therefore	  any	  part	  of	   the	  heart	   taken	  11	  
might	  show	  fibrosis,	  the	  fibrosis	  in	  ISHD	  is	  more	  likely	  to	  be	  localized	  in	  or	  close	  to	  the	  infarct	  area.	  This	  could	  12	  
explain	  why	  we	  found	  very	  little	  fibrosis	  in	  the	  ISHD	  samples.	  	  13	  
	  14	  
PKA-­‐mediated	  hypophosphorylation	  in	  all	  dilated	  cardiomyopathies	  15	  
Independent	  of	  the	  initial	  cause,	  all	  forms	  of	  dilated	  cardiomyopathy	  (PPCM,	  DCM	  and	  ISHD)	  exhibited	  higher	  16	  
myofilament	   Ca2+-­‐sensitivity	   compared	   to	   controls,	   while	   only	   PPCM	   samples	   had	   an	   increased	   Fpass.	   The	  17	  
increase	   in	  myofilament	   Ca2+-­‐sensitivity	   was	   attributed	   to	   decreased	   PKA-­‐mediated	   phosphorylation	   of	   cTnI	  18	  
since	   incubation	  with	  exogenous	  PKA	   restored	  Ca2+-­‐sensitivity	   to	   controls	   in	  all	   groups.	  The	   increased	  Fpass	   in	  19	  
PPCM	  samples	  was	  also	  restored	  with	  exogenous	  PKA	  and	  a	  decreased	  PKA-­‐mediated	  phosphorylation	  of	  titin	  20	  
was	  confirmed	  at	  Ser4010.	  In	  addition,	  we	  also	  found	  a	  decreased	  phosphorylation	  of	  cMyBP-­‐C	  which	  was	  not	  21	  
related	  to	  glutathionylation	  of	  cMyBP-­‐C.	  These	  combined	  results	  strengthen	  the	  suggestion	  that	  PKA-­‐mediated	  22	  
phosphorylation	   was	   impaired	   in	   all	   heart	   failure	   samples.	   The	   β-­‐adrenergic	   receptors	   were	   shown	   to	   be	  23	  
desensitized	   leading	   to	   impaired	   PKA-­‐mediated	   phosphorylation	   of	   sarcomeric	   proteins	   in	   various	   forms	   of	  24	  
heart	   failure41	  and	  we	  have	  now	  confirmed	  PKA-­‐mediated	  phosphorylation	   is	   impaired	   in	  end-­‐stage	  PPCM	  as	  25	  
well.	  Despite	  a	  similar	  downregulation	  of	  cTnI	  phosphorylation,	   the	  ΔEC50	  was	  significantly	  decreased	  only	   in	  26	  
PPCM	   samples	   compared	   to	   controls.	   While	   DCM	   samples	   showed	   a	   non-­‐significant	   impairment	   of	   length-­‐27	  
dependent	   activation,	   ISHD	   samples	   had	   normal	   length-­‐dependent	   activation	   values	   compared	   to	   controls	  28	  
despite	   their	   increased	   Ca2+-­‐sensitivity.	   A	   decreased	   length-­‐dependent	   activation	   has	   been	   reported	   for	  29	  
16	  
	  
samples	   with	   compliant	   titin35,	   53,	   and	   an	   increase	   in	   compliant	   titin	   has	   been	   reported	   in	   DCM36,	   37.	   We	  1	  
observed	   an	   increase	   in	   N2BA/N2B	   ratio	   in	   PPCM	   and	   DCM	   samples	   compared	   to	   controls.	   In	   addition,	   an	  2	  
increase	  in	  size	  of	  the	  compliant	  titin	  isoform	  was	  found	  corresponded	  to	  58	  kDa	  in	  PPCM,	  93	  kDa	  in	  DCM	  and	  3	  
48	  kDa	  in	  ISHD	  samples	  compared	  to	  controls.	  Although	  this	   increase	  was	  not	  significant,	   it	   is	  of	  a	  magnitude	  4	  
that	   should	  not	  be	   ignored	  since	  such	  an	   increase	   in	  molecular	  weight	  might	  alter	  protein	   function.	  The	   fact	  5	  
that	  titin	  N2BA	  size	  and	  N2BA/N2B	  ratio	  were	  significantly	  correlated	  in	  DCM	  and	  PPCM	  samples	  indicates	  that	  6	  
the	   same	   regulatory	  mechanism	   is	   responsible	   for	   both	   the	   shift	   in	   isoform	   and	   the	   inclusion	   of	   additional	  7	  
exons	  to	  make	  N2BA	  bigger.	  This	  	  observation	  is	  in	  line	  with	  the	  increase	  in	  titin	  N2BA	  size	  and	  N2BA/N2B	  ratio	  8	  
found	   in	  a	  patient	  with	  a	  mutation	   in	  RBM2024.	  The	  observation	  that	   in	   ISHD	  N2BA	  size	  was	   increased,	  while	  9	  
N2BA/N2B	  ratio	  was	  unaltered	   implies	  the	   isoform	  shift	   is	  preceded	  by	   inclusion	  of	  additional	  exons	   in	  N2BA	  10	  
after	  which	   both	   titin	   size	   and	  N2BA	   expression	   increase	   further.	   Both	   cTnI	   phosphorylation	   as	  well	   as	   titin	  11	  
isoform	   composition	   are	   regulators	   of	   myofilament	   length-­‐dependent	   activation34.	   The	   decreased	   cTnI	  12	  
phosphorylation	  and	  increase	  in	  N2BA/N2B	  and	  N2BA	  size	  explain	  the	  blunted	  myofilament	  length-­‐	  dependent	  13	  
activation	   in	   PPCM	   and	   DCM	   samples.	   The	   preserved	   myofilament	   length-­‐dependent	   activation	   in	   ISHD	  14	  
samples,	  which	  showed	  decreased	  cTnI	  phosphorylation	  and	  unaltered	  N2BA/N2B	  ratio,	  indicates	  a	  synergistic	  15	  
role	  of	  cTnI	  phosphorylation	  and	  titin	  in	  regulating	  myofilament	  length-­‐dependent	  activation.	  	  16	  
	  17	  
Different	  myofilament	  remodeling	  of	  the	  M-­‐band	  in	  PPCM	  and	  DCM	  18	  
PPCM	   and	   DCM	   samples	   both	   had	   decreased	   phosphorylation	   at	   Ser4010	   of	   titin	   and	   a	   similar	   increase	   in	  19	  
N2BA/N2B	   ratio,	   while	   Fpass	   was	   higher	   compared	   to	   controls	   only	   in	   PPCM.	   The	   expression	   of	   myomesin	  20	  
isoforms	  follows	  the	  expression	  of	  titin	  isoforms	  in	  various	  muscle	  types.	  The	  longer	  compliant	  isoforms	  of	  titin	  21	  
and	  EH-­‐myomesin	  are	  predominantly	  expressed	   in	  the	  fetal	  heart	  and	  are	  replaced	  by	  the	  shorter	  and	  stiffer	  22	  
myomesin	  during	   the	  progression	   to	   adulthood54,	   55.	   This	  was	   also	   reported	   for	   soleus	  where	   the	   larger	   titin	  23	  
N2A	  isoform56	  is	  expressed,	  the	  EH-­‐myomesin	  dominates57.	  The	  re-­‐expression	  of	  EH-­‐myomesin	  in	  DCM	  patients	  24	  
could	  be	  a	  result	  of	  the	  induction	  of	  the	  fetal	  gene	  program	  which	  has	  been	  shown	  in	  various	  forms	  of	  heart	  25	  
failure	   and	   is	   believed	   to	   be	   activated	   in	   order	   to	   cope	  with	   the	   changes	   in	   cardiac	   demand58.	  Whether	   the	  26	  
expression	  of	  these	  fetal	  genes	  is	  beneficial	  is	  still	  under	  debate.	  EH-­‐myomesin	  acts	  as	  a	  mini-­‐spring	  and	  has	  an	  27	  
additional	  domain	  of	  approximately	  200	  amino	  acids,	  similar	  to	  the	  PEVK	  domain	  of	  titin59.	   It	   is	  believed	  that	  28	  
EH-­‐myomesin	  provides	  stability	   to	   the	  sarcomere	   in	  overstretched	  conditions59.	  Here	  we	  presented	  evidence	  29	  
17	  
	  
that	   expression	   of	   EH-­‐myomesin	   might	   prevent	   an	   increase	   in	   Fpass	   and	   decrease	   of	   length-­‐	   dependent	  1	  
activation	   in	   DCM	   patients,	   but	   not	   in	   PPCM	   patients	   who	   do	   not	   express	   EH-­‐myomesin.	   Exogenous	   PKA	  2	  
restored	  Fpass	  and	   length-­‐	  dependent	  activation	   in	  PPCM	  samples	   indicating	   	   that	   the	   lack	  of	  EH-­‐myomesin	   is	  3	  
overcome	  by	  PKA-­‐mediated	  protein	  phosphorylation.	  An	  in	  vitro	  study	  showed	  phosphorylation	  of	  myomesin	  4	  
at	   Ser-­‐482	   by	   PKA	   and	   subsequent	   disturbance	   of	   the	   interaction	   between	   titin	   (through	  M4	   domain)	   and	  5	  
myomesin	  (My4-­‐My6	  domains)60.	  However,	  Fukuzawa	  et	  al.	  could	  not	  confirm	  titin	  (M4)-­‐myomesin	  (My4-­‐My6)	  6	  
interaction	  in	  a	  pulldown	  assay	  or	  forced	  yeast	  two	  hybrid	  assay.	  In	  addition,	  phosphorylation	  of	  myomesin	  did	  7	  
not	   affect	   myomesin-­‐obscurin	   interaction61.	   Therefore,	   the	   effect	   of	   myomesin	   phosphorylation	   in	   vivo	  8	  
warrants	  further	  research.	  Nonetheless,	  in	  heart	  failure	  where	  the	  β-­‐adrenergic	  receptors	  are	  desensitized	  and	  9	  
PKA-­‐mediated	  phosphorylation	  of	  sarcomeric	  proteins	  such	  as	  cTnI	  and	  titin	  is	  decreased,	  the	  expression	  of	  EH-­‐10	  
myomesin	   may	   play	   an	   important	   role	   in	   stabilization	   of	   the	   sarcomeres	   in	   order	   to	   maintain	   or	   limit	   the	  11	  
increase	  in	  Fpass	  and	  impairment	  of	  length-­‐dependent	  activation.	  	  12	  
	  13	  
Clinical	  perspective	  14	  
Although	  PPCM	  and	  DCM	  have	  similar	  clinical	  phenotypes,	  they	  differ	  in	  their	  clinical	  progression	  and	  therefore	  15	  
have	  a	  different	  prognosis.	  We	  show	  here	  that	  myofilament	  remodeling	  is	  different	  in	  PPCM	  and	  DCM.	  We	  also	  16	  
show	   that	   PPCM	   samples	   suffer	   from	   impaired	   PKA-­‐mediated	   phosphorylation	   similar	   to	   what	   has	   been	  17	  
observed	  in	  DCM	  samples,	  but	  that	  the	  effect	  on	  myofilament	  function	  is	   larger	  in	  PPCM.	  These	  observations	  18	  
could	  provide	  a	  possible	  explanation	  why	  PPCM	  patients	  have	  such	  a	  strong	  response	  to	  stimulation	  of	  their	  β-­‐19	  
adrenergic	  system20.	  The	  notion	  that	  we	  could	  restore	  all	  parameters	  with	  exogenous	  PKA	  indicates	  that	  both	  20	  
PPCM	   and	   DCM	   patients	   might	   benefit	   from	   an	   increase	   in	   β-­‐adrenergic	   stimulation	   in	   order	   to	   normalize	  21	  
myofilament	   function.	  However	  we	  have	  discussed	  before	  that	  dobutamine,	  a	  β-­‐adrenergic	   receptor	  agonist,	  22	  
worsens	   heart	   failure	   in	   PPCM	   patients	   and	   STAT3	   KO	   mice,	   and	   is	   associated	   with	   adverse	   outcome	  23	  
independent	  of	  treatment	  with	  bromocriptine13,	  20.	  These	  results	  question	  whether	  the	  β-­‐adrenergic	  system	  is	  24	  
therefore	  a	   realistic	  clinical	   target	   in	  PPCM	  treatment.	  However,	   increasing	  Ca2+-­‐sensitivity	  has	  been	  a	   target	  25	  
for	  the	  treatment	  of	  systolic	  dysfunction	  since	  a	  greater	  force	  is	  generated	  at	  lower	  calcium	  concentrations	  in	  26	  
order	   to	   achieve	   sufficient	   contractile	   power	   in	   systolic	   dysfunction.	   We	   show	   that	   the	   myofilaments	   are	  27	  
already	  very	  Ca2+	  sensitive	  and	  this	  should	  be	  taken	   into	  consideration	  when	  considering	  high	  Ca2+-­‐sensitivity	  28	  
18	  
	  
might	   impair	   .	   In	   addition,	   too	   length-­‐dependent	   activation	   high	   Ca2+-­‐sensitivity	   might	   cause	   contraction	   at	  1	  
diastolic	  calcium	  concentrations	  and	  thereby	  contributes	  to	  cardiac	  dysfunction.	  	  2	  
	  3	  
Conclusion	  4	  
We	   show	   that	   different	   forms	   of	   heart	   failure;	   PPCM,	   DCM	   and	   ISHD,	   share	   aspects	   of	   underlying	  5	  
pathomechanisms	  but	  they	  also	  differ	  in	  important	  aspects.	  An	  overview	  of	  the	  changes	  in	  each	  form	  of	  heart	  6	  
failure	   is	   shown	   in	   Figure	   6.	   PPCM,	  DCM	  and	   ISHD	  have	   decreased	   cMyBP-­‐C	   phosphorylation	   and	   increased	  7	  
Ca2+-­‐sensitivity	   induced	   by	   decreased	   phosphorylation	   of	   cTnI.	   However,	   PPCM	   and	   DCM	   share	   additional	  8	  
pathomechanisms	  such	  as	  increased	  compliant	  titin,	  reduced	  phosphorylation	  of	  titin	  at	  Ser4010	  and	  impaired	  9	  
myofilament	   length-­‐dependent	   activation,	   observations	   that	   were	   not	   seen	   in	   ISHD.	   The	   increase	   in	  10	  
myofilament	   Ca2+-­‐sensitivity	   and	   decreased	   length-­‐dependent	   activation	   was	   more	   pronounced	   in	   PPCM	  11	  
samples.	  Both	  parameters	  could	  be	   restored	  after	   incubation	  with	  exogenous	  PKA.	   In	  addition,	  DCM	  but	  not	  12	  
PPCM	   patients	   show	   induction	   of	   the	   expression	   of	   EH-­‐myomesin.	   The	   lack	   of	   EH-­‐myomesin	   re-­‐expression	  13	  
might	   have	   contributed	   to	   an	   increase	   in	   Fpass	   and	   severely	   blunted	   length-­‐	   dependent	   activation	   in	   PPCM	  14	  
patients	   in	   situations	   of	   low	   PKA-­‐mediated	   phosphorylation	   due	   to	   instability	   of	   the	   sarcomeres	   in	  15	  
overstretched	  conditions.	  Therefore,	  this	  study	  shows	  myofilament	  remodeling	  and	  function	  is	  more	  impaired	  16	  
in	   PPCM	   compared	   to	   DCM	   and	   ISHD,	   and	   the	   lack	   of	   EH-­‐myomesin	   re-­‐expression	   may	   explain	   the	   fast	  17	  
deterioration	  of	  some	  PPCM	  patients	  to	  end-­‐stage	  heart	  failure.	  18	  
	  19	  
Limitation	  to	  the	  study	  20	  
No	   tissue	   from	   healthy	   postpartum	   women	   could	   be	   explored	   and	   therefore	   the	   condition	   of	   a	   healthy	  21	  
maternal	  heart	  in	  the	  postpartum	  phase	  is	  not	  known.	  In	  addition,	  the	  different	  heart	  failure	  groups	  could	  not	  22	  
be	   completely	   matched	   regarding	   age	   and	   gender	   of	   patient	   samples	   studied.	   However,	   no	   difference	   was	  23	  
observed	  between	  samples	  derived	  from	  males	  and	  females	  in	  the	  DCM	  group.	  	  24	  
	  25	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  10	  
Figure	  1.	  Baseline	  characteristics	  11	  
A:	  Fmax	  was	  not	  significantly	  different	  in	  PPCM	  (25.1±2.3	  kN/m
2,	  N=4,	  n=16),	  DCM	  (27.9±1.7	  kN/m2,	  N=6,	  n=27)	  12	  
and	   ISHD	   (30.9±1.9	   kN/m2,	   N=4,	   n=15)	   compared	   to	   controls	   (29.7±1.8	   kN/m2,	   N=7,	   n=30).	   B:	   Fpass	   was	  13	  
significantly	   increased	   in	   PPCM	   (N=4,	   n=14,	   p<0.0001)	   compared	   to	   controls	   (N=7,	   n=18).	   Fpass	   was	   not	  14	  
significantly	  altered	  in	  DCM	  (N=6,	  n=15)	  and	  ISHD	  (N=4,	  n=9)	  compared	  to	  controls.	  C:	  The	  force-­‐calcium	  curve	  15	  
was	  shifted	  to	  the	  left	  compared	  in	  PPCM	  (N=4,	  n=8),	  DCM	  (N=6,	  n=13)	  and	  ISHD	  (N=4,	  n=6)	  samples	  compared	  16	  
to	  controls	   (N=7,	  n=17).	  D:	  Ca2+-­‐sensitivity,	  measured	  as	  EC50,	  was	  significantly	   increased	   in	  PPCM	  (1.19±0.08	  17	  
μM,	   N=4,	   n=8,	   p<0.0001),	   DCM	   (1.27±0.08	   μM,	   N=6,	   n=13,	   p<0.0001)	   and	   ISHD	   (1.25±0.10	   μM,	   N=4,	   n=6,	  18	  
p<0.0001)	  	  compared	  to	  controls	  (1.84	  ±0.05	  μM,	  N=7,	  n=17).	  E:	  Length-­‐dependent	  activation,	  indicated	  by	  the	  19	  
increase	   in	   Ca2+-­‐sensitivity	   upon	   stretch,	   was	   decreased	   in	   PPCM	   and	   DCM,	   but	   not	   in	   ISHD	   compared	   to	  20	  
controls.	  F:	  The	  shift	   in	  Ca2+-­‐sensitivity,	   indicated	  by	  ΔEC50	  was	  significantly	   reduced	   in	  PPCM	  (0.26±0.05	  μM,	  21	  
N=4,	  n=8,	  p=0.0234)	  compared	  to	  controls	  (0.54	  ±0.08	  μM,	  N=7,	  n=17),	  while	  it	  was	  non-­‐significantly	  reduced	  in	  22	  
DCM	  (0.41±0.03	  μM,	  N=6,	  n=13)	  and	  similar	  to	  controls	  in	  ISHD	  (0.52±0.06	  μM,	  N=4,	  n=6).	  	  	  23	  
	  24	  
Figure	  2:	  Titin	  isoform	  shift	  in	  DCM	  and	  PPCM	  and	  fibrosis	  in	  all	  dilated	  cardiomyopathies	  25	  
A:	  Titin	  isoforms	  N2BA	  and	  N2B	  were	  separated	  with	  gel	  electrophoresis.	  B:	  N2BA/N2B	  was	  increased	  in	  DCM	  26	  
(0.84±0.16,	  N=8,	  p=0.0327)	  and	  non-­‐significantly	   in	  PPCM	  (0.82±0.15,	  N=6),	  but	  not	   in	   ISHD	  (0.43±0.07,	  N=4)	  27	  
compared	   to	   controls	   (0.52±0.02,	   N=15).	   C:	   The	   size	   of	   N2BA	   titin	   was	   non-­‐significantly	   increased	   in	   DCM	  28	  
(3471±39	  kDa,	  N=8)	  and	  PPCM	  (3446±39	  kDa,	  N=5)	  compared	  to	  controls	  (3388±16	  kDa,	  N=9)	  while	  a	  smaller	  29	  
20	  
	  
increase	  in	  N2BA	  size	  was	  observed	  in	  ISHD	  (3436±7	  kDa,	  N=4).	  D:	  The	  size	  of	  N2BA	  was	  significantly	  correlated	  1	  
to	   the	   N2BA/N2B	   ratio	   in	   PPCM	   (p=0.0479,	   R2=0.7775)	   and	   DCM	   (p=0.0365,	   R2=0.5450),	   but	   not	   in	   ISHD,	  2	  
controls	  or	  all	   groups	   combined.	  E:	  Representative	  pictures	  of	   cryosections	   stained	  with	  picro-­‐Sirius	   red	  of	  a	  3	  
control,	   PPCM,	   DCM	   and	   ISHD	   sample.	   F:	   Fibrosis	   was	   significantly	   increased	   in	   PPCM	   (4.51±0.66%,	   N=4,	  4	  
p=0.0003)	  and	  DCM	  (5.46±0.55%,	  N=8,	  p<0.0001)	  compared	  to	  controls	  (1.21±0.23%,	  N=9),	  while	  fibrosis	  was	  5	  
only	  non-­‐significantly	   increased	   in	   ISHD	   (2.92±0.46%,	  N=4).	  G:	  No	   significant	   correlation	  was	   found	  between	  6	  
the	  amount	  of	  fibrosis	  and	  N2BA/N2B.	  	  7	  
	  8	  
Figure	  3:	  Glutathionylation	  and	  phosphorylation	  of	  MyBP-­‐C	  9	  
A:	   Upper	   panel:	   gel	   stained	   with	   ProQ	   diamond.	   Lower	   panel:	   same	   gel	   stained	   with	   SYPRO	   Ruby.	   B:	  10	  
Phosphorylation	  of	   cMyBP-­‐C	  was	   significantly	  decreased	   in	  PPCM	  (N=5,	  p=0.0125),	  DCM	  (N=6	  p=0.0027)	  and	  11	  
ISHD	  (N=4,	  p=0.0011)	  compared	  to	  controls	  (N=13).	  C:	  Representative	  blots	  stained	  with	  α-­‐glutathione	  (upper	  12	  
panel),	  cMyBP-­‐C	  (lower	  panel).	  D:	  Glutathionylation	  of	  cMyBP-­‐C	  was	  not	  different	  in	  PPCM	  (N=4),	  DCM	  (N=4)	  13	  
and	   ISHD	   (N=3)	   compared	   to	   controls	   (N=11).	   E:	   No	   correlation	   was	   found	   between	   gluthationylation	   and	  14	  
phosphorylation	  of	  cMyBP-­‐C.	  	  15	  
	  16	  
Figure	  4:	  Impaired	  β-­‐adrenergic	  signaling	  in	  PPCM,	  DCM	  and	  ISHD	  17	  
A:	   Representative	   pictures	   of	   phosphorylated	   titin	   at	   Ser4010	   (upper	   panel)	   and	   total	   titin	   (lower	   panel).	  B:	  18	  
Representative	  pictures	  of	  phosphorylated	  titin	  at	  Ser12022	  (upper	  panel)	  and	  total	  titin	  (lower	  panel).	  C:	  PKA-­‐19	  
mediated	   phosphorylation	   of	   titin	   at	   Ser4010	   was	   significantly	   reduced	   in	   PPCM	   (N=5,	   p=0.0140)	   and	   DCM	  20	  
samples	  (N=6,	  p=0.0051)	  compared	  to	  controls	  (N=12)	  while	  it	  was	  not	  altered	  in	  ISHD	  samples	  (N=4).	  D:	  PKC	  21	  
mediated	  phosphorylation	  of	   titin	  at	   Ser12022	  was	  non-­‐significantly	  decreased	   in	  PPCM	   (N=4)	  but	  normal	   in	  22	  
DCM	  (N=6)	  and	   ISHD	  (N=3)	  samples	  compared	  to	  controls	   (N=11).	  E:	  Fpass	  normalized	  to	  controls	   (N=7,	  n=14)	  23	  
after	   incubation	  with	  exogenous	  PKA	   in	  PPCM	  samples	   (N=4,	  n=11),	  while	   it	   did	  not	   alter	   Fpass	   in	  DCM	   (N=6,	  24	  
n=11)	   or	   ISHD	   (N=4,	   n=10)	   samples.	   F:	   Phosphorylation	   of	   cTnI	   was	   significantly	   reduced	   in	   PPCM	   (N=5,	  25	  
p=0.0004)	   and	   DCM	   (N=6,	   p=0.001)	   and	   non-­‐significantly	   in	   ISHD	   (N=4,	   p=0.0681)	   samples	   compared	   to	  26	  
controls	   (N=13).	  G:	   PhosTag	  analysis	   showed	   separation	  of	  non-­‐,	  mono-­‐	  and	  bis-­‐	  phosphorylation	  of	   cTnI.	  H:	  27	  
PhosTag	  analysis	  showed	  predominantly	  mono-­‐and	  bisphosphorylation	  of	  cTnI	  in	  controls	  (N=8)	  while	  non-­‐	  and	  28	  
mono-­‐phosphorylation	  was	  more	  prevalent	  in	  PPCM	  (N=5)	  and	  DCM	  (N=6).	  ISHD	  samples	  (N=3)	  showed	  mostly	  29	  
21	  
	  
mono-­‐phosphorylation	   of	   cTnI.	   I:	   Incubation	   with	   exogenous	   PKA	   normalized	   Ca2+-­‐sensitivity	   in	   PPCM	  1	  
(1.79±0.12,	   N=5	   n=8),	   DCM	   (2.02±0.09,	   N=6,	   n=8)	   and	   ISHD	   (2.01±0.15,	   N=4,	   n=6)	   samples	   compared	   to	  2	  
controls	   (1.81±0.06,	  N=6,	   n=17).	   J:	   Length-­‐dependent	   activation,	   indicated	   by	   the	   increase	   in	   Ca2+-­‐sensitivity	  3	  
upon	  stretch,	  was	  normalized	  after	  incubation	  with	  exogenous	  PKA	  to	  controls	  in	  PPCM	  (N=5	  n=8),	  DCM	  (N=6,	  4	  
n=8)	   and	   ISHD	   (N=4,	   n=6)	   samples	   compared	   to	   controls	   (N=6,	   n=17).	   K:	   The	   shift	   in	   Ca2+-­‐sensitivity	   upon	  5	  
stretch,	   indicated	   by	   ΔEC50	   was	   normalized	   to	   controls	   after	   incubation	   with	   exogenous	   PKA	   in	   PPCM	  6	  
(0.51±0.09,	   N=5	   n=8),	   DCM	   (0.58±0.08,	   N=6,	   n=8)	   and	   ISHD	   (0.63±0.11,	   N=4,	   n=6)	   samples	   compared	   to	  7	  
controls	  (0.53±0.07,	  N=6,	  n=17).	  8	  
	  9	  
Figure	  5:	  EH-­‐myomesin	  expression	  in	  DCM,	  but	  only	  limited	  in	  PPCM	  and	  ISHD	  compared	  to	  controls	  10	  
Representative	   immunohistochemical	  pictures	  of	   controls	   (A),	  PPCM	   (B),	  DCM	   (C)	   and	   ISHD	   (D)	   in	  which	  EH-­‐11	  
myomesin	   is	  stained	   in	  green,	  all	  myomesin	   isoforms	   in	  red	  and	  nuclei	   in	  blue.	  The	  percentage	  of	  patients	   in	  12	  
control	   (E),	  PPCM	  (F),	  DCM	  (G)	  and	   ISHD	  (H)	  groups	  that	   fall	   in	  various	  categories	  of	  degree	  of	  EH-­‐myomesin	  13	  
expression	  is	  indicated	  in	  pie	  charts.	  I:	  Western	  blot	  showed	  EH-­‐myomesin	  expression	  (upper	  panel)	  relative	  to	  14	  
actin	  (lower	  panel)	  is	  non-­‐significantly	  increased	  in	  DCM	  (N=4)	  compared	  to	  PPCM	  (N=4)	  and	  controls	  (N=2)	  (J).	  	  15	  
	  16	  
Figure	  6:	  Overview	  of	  pathological	  changes	  in	  PPCM,	  DCM	  and	  ISHD	  17	  
All	  dilated	  cardiomyopathies	  showed	  a	  decreased	  cMyBP-­‐C	  phosphorylation	  and	  an	  increase	  in	  Ca2+-­‐sensitivity	  18	  
induced	  by	  decreased	  phosphorylation	  of	  cTnI.	  However,	  PPCM	  and	  DCM	  share	  additional	  pathomechanisms	  19	  
such	  as	  increased	  compliant	  titin,	  reduced	  phosphorylation	  of	  titin	  at	  Ser4010	  and	  impaired	  length-­‐dependent	  20	  
activation.	   Phosphorylation	  of	   titin	   Ser-­‐12022	  was	  only	  decreased	   in	  PPCM.	  While	  DCM	  samples	   showed	   re-­‐21	  
expression	  of	  EH-­‐myomesin,	  PPCM	  and	  ISHD	  samples	  did	  not.	  The	  lack	  of	  EH-­‐myomesin	  re-­‐expression	  in	  PPCM	  22	  
in	   combination	  with	   low	  cTnI	  phosphorylation	  and	  enhanced	   compliant	   titin	   isoform	  expression	  may	  explain	  	  23	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Supplemental	  Figure	  1.	  Assessment	  of	  Ca2+-­‐sensitivity,	  EC50	  and	  length-­‐dependent	  activation	  
Representatve	  relative	  force-­‐[Ca2+]	  curves	  are	  shown	  of	  a	  permeabilized	  cardiomyocyte	  measured	  at	  sarcomere	  
length	  1.9	  μm	  and	  2.3	  μm.	  Force	  of	  each	  cell	  was	  normalized	   to	   its	  Fmax	  at	  both	   lengths.	  Ca
2+-­‐sensitivity	  was	  
expressed	  as	  the	  [Ca2+]	  needed	  to	  achieve	  50%	  of	  Fmax	  (EC50)	  and	  length-­‐dependent	  activation	  was	  measured	  as	  




Supplemental	  Figure	  2.	  Determination	  of	  titin	  size.	  
A:	   Titin	   isoforms	   were	   separated	   on	   a	   1%	   agarose	   gel	   with	   electrophoresis.	   B:	   A	   calibration	   curve	   was	  
constructed	  based	  on	  mobility	  of	  proteins	  of	  known	  molecular	  weight	  (N2A	  soleus	  3690	  kDa;	  	  N2B	  non-­‐failing	  
heart	  2970	  kDa;	  nebulin	  soleus	  muscle	  748	  kDa	  and	  myosin	  heavy	  chain	   (MHC)	  200	  kDa)	   relative	   to	  MHC.	   In	  
order	  to	  avoid	  gel-­‐to-­‐gel	  variation	  or	  variation	   in	  mobility	  within	  a	  gel,	  only	  the	  adjacent	   lanes	  were	  used	  for	  
the	  construction	  of	  the	  calibration	  curve.	  This	  calibration	  curve	  was	  used	  to	  calculate	  the	  molecular	  weight	  of	  
the	  N2BA	  titin	  band	  of	  the	  sample	  of	  interest	  based	  on	  relative	  mobility	  to	  MHC.	  
	  
	  	  
Supplemental	  Figure	  3.	  Positive	  and	  negative	  controls	  for	  glutathionylation	  western	  blots	  
A:	  Positive	  and	  negative	  controls	  were	  produced	  by	  treating	  isolated	  adult	  rat	  cardiomyocytes	  with	  reducing	  or	  
oxidizing	   compounds.	   Negative	   controls	   	   were	   obtained	   by	   treating	   homogenates	   with	   the	   reducing	  
compounds	  DTT	  and	  BME.	  Positive	  controls	  showed	  increased	  glutathione	  signal	  after	  incubation	  with	  diamide,	  
a	   inducer	   of	   glutathionylation,	   in	   a	   dose	   dependent	  manner.	  B:	   Quantified	   glutathionylation	   of	   positive	   and	  
negative	  controls.	  The	  band	  used	  for	  analysis	  is	  indicated	  in	  A.	  	  
	  
